BioCentury | Jan 9, 2021
Translation in Brief

Fusing camelid antibodies to toxin derivatives to treat botulism; plus BioNTech applies platform to multiple sclerosis, a molecule that stops axon degeneration and more

...fused to BoNT derivatives shortened the duration of muscle paralysis and increased survival in mice. Wake Forest...
...December.TARGETSSARM1 – Sterile alpha and TIR motif containing 1 Danielle Golovin Revlimid, lenalidomide (cdc 501, CC-5013) Boston Children's Hospital Wake Forest University New...
BioCentury | Feb 22, 2020
Translation in Brief

Storm's open-access algorithm for RNA epigenetics; plus Duke studies show checkpoint blockers promote anti-HIV bNAbs and reduce opioid efficacy

...PD-1 inhibition may interfere with cancer patients' pain medication. Led by scientists at Duke and Wake Forest University...
BioCentury | Nov 22, 2019
Emerging Company Profile

Morphiex’s antisense take on CD47 aims for more than eating

...by Anthony Schwartz and Chris Garabedian University collaborators: National Cancer Institute, National Institutes of Health, Wake Forest University...
BioCentury | Aug 13, 2019
Clinical News

Taltz tops Tremfya in psoriasis but data may not change prescribing habits

...would have better efficacy than Tremfya," he said. Feldman is a professor of dermatology at Wake Forest...
...LY2439821 (Compound #), ixekizumab (Generic), Taltz (Other) Tremfya, guselkumab (CNTO 1959) AbbVie Inc. Eli Lilly and Co. Johnson & Johnson Wake Forest University Interleukin-17A...
BioCentury | Jul 25, 2019
Distillery Therapeutics

Inhibiting the IRE1/XBP1 pathway for pain

...Women’s Hospital, Boston, Mass.; Dana-Farber Cancer Institute, Boston, Mass. e-mail: laurie_glimcher@dfci.harvard.edu CONTACT: E. Alfonso Romero-Sandoval, Wake Forest University...
...Weill Cornell Medicine, New York, N.Y. e-mail: jur2016@med.cornell.edu Mary Romeo Brigham and Women's Hospital Dana-Farber Cancer Institute Harvard Medical School Wake Forest University Weill...
BioCentury | Apr 10, 2019
Tools & Techniques

Microbiome makes its mark outside the gut

...triple-negative breast cancer (TNBC), while high levels of Oscillospira and Bacteroidales associate with favorable responses. Wake Forest University...
...Staphylococcu s in the breast tumor microbiome could help predict distal metastases later in life. Wake Forest University...
BioCentury | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

...the field and suggesting targets for tumor microbiomes might be on the near horizon. A Wake Forest University...
...University of Tennessee , Knoxville, Tenn. University of Texas MD Anderson Cancer Center, Houston, Texas Wake Forest University...
BioCentury | Sep 27, 2018
Distillery Therapeutics

Cancer

...of Wake Forest University Baptist Medical Center, Winston-Salem, N.C. email: mnikifor@wakehealth.edu; mikhail.nikiforov@roswellpark.org Michael J. Haas Velcade, bortezomib (LDP-341, MLN341, PS-341) Wake Forest University Aryl...
BioCentury | Sep 7, 2018
Clinical News

Bifunctional agonist could treat pain, opioid dependency

...A team from Astraea Therapeutics LLC (Mountain View, Calif.) and Wake Forest Baptist Medical Center developed a...
...Mountain View, Calif. Product: AT-121 Business: Neurology Indication: Treat pain and opioid dependency Chris Lieu Astraea Therapeutics LLC Wake Forest...
BioCentury | Aug 29, 2018
Preclinical News

Bifunctional agonist could treat pain, opioid dependency

...A team from Astraea Therapeutics LLC (Mountain View, Calif.) and Wake Forest Baptist Medical Center developed a...
...additional studies of AT-121 in preclinical models in preparation for filing an IND. Chris Lieu Astraea Therapeutics LLC Wake Forest...
Items per page:
1 - 10 of 102
BioCentury | Jan 9, 2021
Translation in Brief

Fusing camelid antibodies to toxin derivatives to treat botulism; plus BioNTech applies platform to multiple sclerosis, a molecule that stops axon degeneration and more

...fused to BoNT derivatives shortened the duration of muscle paralysis and increased survival in mice. Wake Forest...
...December.TARGETSSARM1 – Sterile alpha and TIR motif containing 1 Danielle Golovin Revlimid, lenalidomide (cdc 501, CC-5013) Boston Children's Hospital Wake Forest University New...
BioCentury | Feb 22, 2020
Translation in Brief

Storm's open-access algorithm for RNA epigenetics; plus Duke studies show checkpoint blockers promote anti-HIV bNAbs and reduce opioid efficacy

...PD-1 inhibition may interfere with cancer patients' pain medication. Led by scientists at Duke and Wake Forest University...
BioCentury | Nov 22, 2019
Emerging Company Profile

Morphiex’s antisense take on CD47 aims for more than eating

...by Anthony Schwartz and Chris Garabedian University collaborators: National Cancer Institute, National Institutes of Health, Wake Forest University...
BioCentury | Aug 13, 2019
Clinical News

Taltz tops Tremfya in psoriasis but data may not change prescribing habits

...would have better efficacy than Tremfya," he said. Feldman is a professor of dermatology at Wake Forest...
...LY2439821 (Compound #), ixekizumab (Generic), Taltz (Other) Tremfya, guselkumab (CNTO 1959) AbbVie Inc. Eli Lilly and Co. Johnson & Johnson Wake Forest University Interleukin-17A...
BioCentury | Jul 25, 2019
Distillery Therapeutics

Inhibiting the IRE1/XBP1 pathway for pain

...Women’s Hospital, Boston, Mass.; Dana-Farber Cancer Institute, Boston, Mass. e-mail: laurie_glimcher@dfci.harvard.edu CONTACT: E. Alfonso Romero-Sandoval, Wake Forest University...
...Weill Cornell Medicine, New York, N.Y. e-mail: jur2016@med.cornell.edu Mary Romeo Brigham and Women's Hospital Dana-Farber Cancer Institute Harvard Medical School Wake Forest University Weill...
BioCentury | Apr 10, 2019
Tools & Techniques

Microbiome makes its mark outside the gut

...triple-negative breast cancer (TNBC), while high levels of Oscillospira and Bacteroidales associate with favorable responses. Wake Forest University...
...Staphylococcu s in the breast tumor microbiome could help predict distal metastases later in life. Wake Forest University...
BioCentury | Mar 29, 2019
Targets & Mechanisms

AACR moves in a myeloid direction

...the field and suggesting targets for tumor microbiomes might be on the near horizon. A Wake Forest University...
...University of Tennessee , Knoxville, Tenn. University of Texas MD Anderson Cancer Center, Houston, Texas Wake Forest University...
BioCentury | Sep 27, 2018
Distillery Therapeutics

Cancer

...of Wake Forest University Baptist Medical Center, Winston-Salem, N.C. email: mnikifor@wakehealth.edu; mikhail.nikiforov@roswellpark.org Michael J. Haas Velcade, bortezomib (LDP-341, MLN341, PS-341) Wake Forest University Aryl...
BioCentury | Sep 7, 2018
Clinical News

Bifunctional agonist could treat pain, opioid dependency

...A team from Astraea Therapeutics LLC (Mountain View, Calif.) and Wake Forest Baptist Medical Center developed a...
...Mountain View, Calif. Product: AT-121 Business: Neurology Indication: Treat pain and opioid dependency Chris Lieu Astraea Therapeutics LLC Wake Forest...
BioCentury | Aug 29, 2018
Preclinical News

Bifunctional agonist could treat pain, opioid dependency

...A team from Astraea Therapeutics LLC (Mountain View, Calif.) and Wake Forest Baptist Medical Center developed a...
...additional studies of AT-121 in preclinical models in preparation for filing an IND. Chris Lieu Astraea Therapeutics LLC Wake Forest...
Items per page:
1 - 10 of 102